BioCentury | Apr 23, 2020

In Hong Kong’s largest biotech IPO of the year, antibody company Akeso raises $333M

Akeso raised HK$2.6 billion Thursday in the second and largest IPO this year on the Hong Kong exchange's biotech chapter, valuing the company at HK$12.3 billion. Akeso Inc. (HKEX:9926) sold 159.5 million shares at HK$16.18,...
BioCentury | Apr 15, 2020

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

Perspectum raises $36M for digital diagnostics Perspectum Diagnostics Ltd. raised $36 million in an undisclosed round co-led by Blue Venture Fund and HealthQuest Capital, with participation from Oxford Science Innovation, Puhua Capital, the University of...
BioCentury | Dec 11, 2019
Financial News

Dec. 10 Financial Quick Takes: Inscripta, Aurinia, Akeso, Ribo, Hummingbird, ImmunOs, Peregrine

Inscripta raises $125M series D Inscripta Inc. raised $125 million in a series D round led by existing investor Paladin Capital, bringing the total capital raised by the company to $260 million since 2015. New...
BioCentury | Nov 5, 2019
Financial News

Following JV, Sino backs Akeso's $150M series D

Six months after establishing a joint venture with Akeso, Sino Biopharmaceutical has co-led a series D round of about $150 million in the Zhongshan-based cancer and autoimmune company. Loyal Valley Capital co-led the round, which...
BioCentury | Jun 19, 2019
Company News

June 18 Company Quick Takes: Sino-Akeso JV, plus Oxford Drug Design, Be The Match and more

CTTQ, Akeso form JV to develop PD-1 mAb The Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) subsidiary of Sino Biopharmaceutical Ltd. (HKEX:1177) formed a 50/50 joint venture with Akeso Biopharma Inc. (Zhongshan, China) to...
Items per page:
1 - 5 of 5